La vendita allo scoperto per Harmony Biosciences Hldgs dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Harmony Biosciences Hldgs. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Harmony Biosciences Hldgs (NASDAQ:HRMY) Azioni, Report sulle vendite allo scoperto

HARMONY BIOSCIENCES HOLDINGS

Harmony Biosciences

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Harmony Biosciences Hldgs

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Holdings Inc

Analyst Ratings

Trading Ideas

CSCO

QCOM

Live On CNBC, Jim Lebenthal Announced Bought More Cisco; Bought More Qualcomm

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 5 years by 16.18% on an annualized basis producing an average annual return of 29.4%. Currently, Amphenol has a market capitalization of $111.72 billion. 
Buying $100 In APH: If an investor had bought $100 of APH stock 5 years ago, it would be worth $354.53 today based on a price of $92.25 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749053712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

$100 Invested In Amphenol 5 Years Ago Would Be Worth This Much Today

General

On June 3, 2025 Enterprise Products Partners Received Notice From The U.S. Department Of Commerce's Bureau Of Industry And Security Of BIS's Intent To Deny Emergency Authorization Requests With Regard To Three Proposed Cargoes Of Ethane To China, Totaling Approximately 2.2M Barrels

The Magnificent Seven did not disappoint in May, posting a <a href="https://www.benzinga.com/etfs/new-etfs/25/06/45722678/magnificent-seven-closed-a-blockbuster-may-added-nearly-2-trillion-in-market-value">record-breaking $1.75 trillion in collective market cap gain</a>, their strongest combined performance in years. 
The center of the mania: the Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>), which saw its best monthly performance since inception, powered by an AI-driven, earnings-supported technology surge.
But with valuations sky-high and Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) in reverse gear, is this still a time to buy, or has the market become too magnificent for its own good?
Benzinga spoke to David Mazza, <a href="https://www.benzinga.com/topic/david-mazza">CEO of Roundhill Investments</a>, to discuss the factors behind MAGS&#8217; &#8220;best month since inception&#8221; and whether the <a href="https://www.benzinga.com/etfs">ETF&#8217;s star status</a> still shines through in changing macro winds.
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/45774924/apple-stock-too-pricey-analyst-warns-of-rising-competition-tariff-risks-favors-2-tech-giants">Apple Stock Too Pricey? Analyst Warns Of Rising Competition, Tariff Risks, Favors 2 Tech Giants</a>
<h2 class="wp-block-heading">Broad-Based Gains, Not Just A One-Stock Show</h2>
&#8220;What stood out was the breadth of the rally,&#8221; Mazza said in an interview with Benzinga. &#8220;Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) led with a 24% gain, but Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) also posted double-digit gains, signaling a broad-based resurgence in the mega caps.&#8221;
The tailwind, Mazza said, was fueled by easing trade tensions and healthy earnings, especially in AI and cloud. &#8220;While we anticipated strength from these companies, the magnitude and breadth of the rally exceeded expectations.&#8221;
Nvidia contributed alone with $639 billion worth of market cap, while Tesla and Meta were not far behind. Microsoft added $484 billion, Amazon increased by $219 billion, and Alphabet added $152 billion.
Also Read:<a href="https://www.benzinga.com/etfs/new-etfs/25/06/45774136/wedbush-launches-ai-revolution-etf-backed-by-dan-ives-proprietary-tech-picks"> Wedbush Launches AI Revolution ETF Backed By Dan Ives&#8217; Proprietary Tech Picks</a>
<h2 class="wp-block-heading">Apple Lags Behind, But MAGS Remains Firm</h2>
The sole laggard among the gang was Apple, which dropped 6%, erasing $192 billion in market capitalization and significantly underperforming the S&amp;P 500. Nevertheless, MAGS&#8217; equal-weighting approach prevented the decline from derailing the ETF&#8217;s performance.
&#8220;Apple&#8217;s underperformance, influenced by trade tensions and delayed AI initiatives, presents a potential buying opportunity,&#8221; Mazza said, highlighting the stock&#8217;s solid ecosystem and diversified manufacturing strategy.
<h2 class="wp-block-heading">Why The Magnificent Seven Still Matter</h2>
More than mere tech giants, Mazza views the Magnificent Seven as critical plumbing to the economy of today. These firms drive everything from cloud computing to e-commerce, he said. &#8220;MAGS focuses exclusively on these companies, providing targeted exposure to the core drivers of modern economic growth.&#8221;
As opposed to the broad tech ETFs that encompass legacy or cyclical names, MAGS is laser-like. And while volatility clouds traditional sectors, some analysts, including Goldman Sachs, have referred to these mega-caps as a &#8220;defensive growth proxy.&#8221;
Mazza does too.
&#8220;These companies combine strong growth prospects with resilient business models, making them attractive during uncertain times. Goldman Sachs&#8217; characterization of them as a &#8216;defensive growth proxy&#8217; aligns with our view,&#8221; he agreed.
<h2 class="wp-block-heading">The Question Of Valuation: Bubble Or Justified?</h2>
With the Magnificent Seven's forward P/E ratio now pushing 27.4x, the ghost of the dot-com bubble inevitably enters the chat. But Mazza sees a key difference.
"While the group&#8217;s median forward P/E ratio has risen to around 27x, it&#8217;s important to note that these valuations are supported by substantial earnings growth and strong fundamentals," he said. "Unlike the dot-com era, these companies are profitable and generate significant cash flow," Mazza noted. Nvidia, for example, posted a 69% YoY revenue jump last quarter.
<h2 class="wp-block-heading">Earnings Outlook And The AI Edge</h2>
Mazza is also optimistic about earnings, citing the group&#8217;s leading position in AI, cloud, and digital services. &#8220;Given their central roles in AI, cloud computing, and digital services, we anticipate continued earnings momentum as demand for these technologies persists and expands across various sectors.&#8221;
While MAGS provides exposure to high-cap AI adopters, Roundhill also has the CHAT ETF available for investors wanting more focused plays on Generative AI.
&#8220;We view AI as a transformative force with long-term implications. The companies within MAGS are not only early adopters, but also key enablers of AI technologies,&#8221; Mazza clarified. 
<h2 class="wp-block-heading">What&#8217;s Next For MAGS?</h2>
Even with the monster rally, Mazza dampens expectations for the remainder of 2025.
&#8220;We don't expect a repeat of the massive gains we saw in the past year, but that doesn't mean the story is over,&#8221; he conceded. &#8220;If earnings growth remains solid and rate expectations stay in check, MAGS could still deliver compelling returns, just more measured than the blockbuster runs we&#8217;ve recently witnessed.&#8221;
With the market still characterized by uncertainty, Mazza feels that Magnificent Seven&#8217;s growth, quality, and macro sensitivity are an elusive combination.
These companies are essential to enterprise and consumer activity,&#8221; he said. &#8220;And MAGS is built to give investors direct exposure to that durability.&#8221;
<h2 class="wp-block-heading">Bottom Line</h2>
May might have been magnificent, but the future of MAGS will be more measured, not muted. For those who want a high-conviction wager on AI, cloud, and the core players in the digital economy, Mazza makes the case the ETF is a singularly focused yet compelling entry point.
After all, in a world short on clarity, the Magnificent Seven might just be the market&#8217;s most down-to-earth stars.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/45771855/vistashares-unleashes-wild-a-2x-leveraged-etf-powered-by-animal-spirits-and-market-momentum">VistaShares Unleashes WILD, A 2x Leveraged ETF Powered By Animal Spirits And Market Momentum</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

Exclusives

Tech

ETFs

AAPL

AMZN

GOOGL

MAGS

MSFT

NVDA

TSLA

David Mazza On MAGS' Magnificent May: 'The Breadth Of The Rally Stood Out'

Loop Capital analyst Mark Schappel maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $220 to $245.

Price Target

SNOW

Loop Capital Maintains Buy on Snowflake, Raises Price Target to $245

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) re-elected all current directors on Wednesday. The board authorized the payment of a cash dividend of $2.21 per share, up from the <a href="https://www.unitedhealthgroup.com/investors/stock.html" target="_blank" rel="noopener">prior</a> dividend of $2.10, to be paid June 24 to common stock shareholders of record as of the close of <a href="https://www.benzinga.com/pressreleases/25/06/b45766386/unitedhealth-group-updates-on-annual-shareholder-meeting-board-actions" target="_blank" rel="noreferrer noopener">business June 16</a>.
In May, UnitedHealth Group&#8217;s CEO&nbsp;, Andrew Witty,&nbsp;resigned for personal reasons. Stephen Hemsley, who previously held the CEO title from 2006 to 2017,&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">succeeded him</a>. The company also suspended its 2025 outlook.
In an SEC filing on Wednesday, UnitedHealth <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/731766/000073176625000154/unh-20250602.htm" target="_blank" rel="noreferrer noopener">said</a> it canceled the performance-based restricted stock units granted to Witty,
Year to date, UnitedHealth Group&#8217;s stock has plunged almost 40%, with the majority coming after the disappointing fourth-<a href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls" target="_blank" rel="noreferrer noopener">quarter 2024 earnings</a>.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45687019/unh-stock-broken-contrarian-traders-eyeball-recovery" target="_blank" rel="noreferrer noopener">Options Corner: UnitedHealth May Be Broken But Contrarian Traders Eyeball A Recovery</a>
UnitedHealth&#8217;s aggressive growth strategy under Witty exposed the healthcare giant to mounting regulatory scrutiny, soaring costs, and a <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">shifting Medicare landscape</a>.
UnitedHealth plans to enlist independent experts to examine its Medicare billing practices, which were criticized following a Wall Street Journal <a href="https://www.benzinga.com/general/health-care/25/05/45443695/why-is-unitedhealth-stock-trading-lower-on-thursday" target="_blank" rel="noreferrer noopener">investigation last year</a>.
Hemsley is stepping forward to acknowledge the fallout and chart a new course, promising a comprehensive review of some of the company's most controversial practices.
The Wall Street Journal noted in its report on the company's annual shareholder meeting on Monday that Hemsley apologized for UnitedHealth's recent performance and cited a need to rethink many internal processes.
He said the company has factored recent results into its 2025 Medicare bids and emphasized a "fresh perspective" on issues that have drawn widespread criticism.
Under Witty, UnitedHealth scaled up its dominance in Medicare Advantage, the privately managed alternative to traditional Medicare.
Former employees said UnitedHealth's profit margins on Medicare enrollees were roughly double those of traditional Medicare insurers.
That advantage stemmed partly from federal rules that limit the premium revenue pure insurers can keep. Additionally, the government pays more for patients with certain chronic diagnoses—a system UnitedHealth capitalized on by gathering such data at high rates.
However, changes announced by the Medicare agency in 2023 altered the rules, reducing or eliminating extra payments for many diagnoses. The changes, phased in starting this year, were expected to have a major financial impact.
An internal analysis <a target="_blank" href="https://www.wsj.com/health/healthcare/unitedhealth-ceo-andrew-witty-medicare-dde1964c" rel="noreferrer noopener">viewed</a> by the WSJ indicated the new rules would significantly reduce the number of reimbursable chronic diagnoses for nearly 900,000 patients.
Despite this, UnitedHealth continued betting on Medicare growth for 2025, even in high-risk patient segments, while rivals pulled back following profit hits in 2024 tied to rising costs.
Hemsley said the company would also examine its pharmacy services and managed care policies, including prior authorization—a process that has faced growing criticism from physicians and patients.
Price Action: UNH stock was flat at $301.29 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs" target="_blank" rel="noreferrer noopener">Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs</a></li>
</ul>
Photo: Piotr Swat / Shutterstock.com

Large Cap

Dividends

Health Care

Management

Movers

UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices

Truist Securities analyst Scot Ciccarelli maintains Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Hold and raises the price target from $93 to $112.

Truist Securities Maintains Hold on Dollar General, Raises Price Target to $112

Truist Securities analyst Joel Fishbein reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and raises the price target from $450 to $500.

Reiteration

CRWD

Truist Securities Reiterates Buy on CrowdStrike Holdings, Raises Price Target to $500

Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>), on Wednesday, announced its lunar and Martian construction tool, Mason, has passed a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45767288/redwire-receives-nasa-approval-to-advance-cutting-edge-manufacturing-technology-for-building-infra" rel="noreferrer noopener">key NASA milestone</a>, completing its Critical Design Review (CDR). The toolset, developed under a $12.9 million NASA Tipping Point award, supports future off-world infrastructure needs.
Mason is designed to turn loose lunar or Martian soil, known as regolith, into solid surfaces like landing pads and roads. It includes three components: a grading blade (BASE), a compaction tool (PACT), and a microwave sintering device (M3LT). Together, they reduce hazards tied to dust and unstable terrain during rocket launches and human activity.
The technology aims to cut costs and improve safety for future space missions. Regolith can damage equipment, reduce mobility, and become airborne during launches, potentially endangering astronauts and satellites.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624626/record-memorial-day-weekend-air-travel-expected-will-airline-stocks-get-a-lift" rel="noreferrer noopener">Space Stocks Weekly Countdown: RocketLab, Blacksky, Redwire &amp; More</a>
Redwire now plans to build and test the Mason prototype. The company is also seeking a flight opportunity for a demonstration mission.
"Mason technology is critical to enabling sustainable operations on the Moon and Mars surface," said Tom Campbell, Redwire's President of Space Missions.
Redwire is working with several partners, including NASA's Kennedy Space Center Swamp Works, Lambda Technologies, the Colorado School of Mines, and the University of Central Florida.
Recently, Redwire <a target="_blank" href="https://www.benzinga.com/news/small-cap/25/05/45624208/why-is-space-technology-company-redwires-stock-is-surging-today" rel="noreferrer noopener">delivered</a> the onboard computer for ESA's Comet Interceptor mission, marking a key milestone with its ADPMS-3 system after completing rigorous acceptance testing. This system enables critical data processing and spacecraft control functions.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Related ETFs: ARK Space Exploration &amp; Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#NYSE">ARKX</a>), SPDR S&amp;P Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>).
Price Action: RDW shares are trading higher by 11.5% to $16.54 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45769775/chart-industries-and-flowserve-announce-19-billion-merger-eyes-300-million-in-synergies" target="_blank" rel="noreferrer noopener">Chart Industries And Flowserve Announce $19 Billion Merger, Eyes $300 Million In Synergies</a></li>
</ul>
Photo by Mer_Studio via Shutterstock

ARKX

Redwire Stock Skyrockets After NASA Clears Lunar Tool Mason For Next Phase

Truist Securities analyst Michael Ciarmoli initiates coverage on TAT Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) with a Buy rating and announces Price Target of $35.

Initiation

TATT

Truist Securities Initiates Coverage On TAT Technologies with Buy Rating, Announces Price Target of $35

Duluth Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTH#NASDAQ">DLTH</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-06-05. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Duluth Holdings will report an earnings per share (EPS) of $-0.42.
The announcement from Duluth Holdings is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.15, leading to a 9.7% drop in the share price on the subsequent day.
Here's a look at Duluth Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.11</td>
<td>-0.32</td>
<td>-0.15</td>
<td>-0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>-0.41</td>
<td>-0.02</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>-0.0%</td>
<td>6.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1749052896_0.png" alt="eps graph" />
<h3>Duluth Holdings Share Price Analysis</h3>
Shares of Duluth Holdings were trading at $2.07 as of June 03. Over the last 52-week period, shares are down 42.9%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Observations about Duluth Holdings</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Duluth Holdings.
The consensus rating for Duluth Holdings is Neutral, derived from 1 analyst ratings. An average one-year price target of $2.75 implies a potential 32.85% upside.
<h3>Peer Ratings Comparison</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Destination XL Group, Tilly's and a.k.a. Brands Holding, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Destination XL Group, with an average 1-year price target of $2.5, suggesting a potential 20.77% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Tilly's, with an average 1-year price target of $2.5, suggesting a potential 20.77% upside.</li>
<li>Analysts currently favor an Buy trajectory for a.k.a. Brands Holding, with an average 1-year price target of $22.43, suggesting a potential 983.57% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Destination XL Group, Tilly's and a.k.a. Brands Holding, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duluth Holdings</td>
<td>Neutral</td>
<td>-1.77%</td>
<td>$106.48M</td>
<td>-1.90%</td>
</tr>
<tr>
<td>Destination XL Group</td>
<td>Buy</td>
<td>-8.62%</td>
<td>$47.58M</td>
<td>-1.38%</td>
</tr>
<tr>
<td>Tilly's</td>
<td>Neutral</td>
<td>-14.87%</td>
<td>$38.27M</td>
<td>-12.70%</td>
</tr>
<tr>
<td>a.k.a. Brands Holding</td>
<td>Buy</td>
<td>10.11%</td>
<td>$73.66M</td>
<td>-7.29%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Duluth Holdings ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity.
<h3>Delving into Duluth Holdings's Background</h3>
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
<h3>Duluth Holdings: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Duluth Holdings's revenue growth over a period of 3 months has faced challenges. As of 31 January, 2025, the company experienced a revenue decline of approximately -1.77%. This indicates a decrease in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Duluth Holdings's net margin excels beyond industry benchmarks, reaching -1.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Duluth Holdings's ROE excels beyond industry benchmarks, reaching -1.9%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Duluth Holdings's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.71%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Duluth Holdings's debt-to-equity ratio is below the industry average at 0.89, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/DLTH/earnings">To track all earnings releases for Duluth Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

DLTH

Insights into Duluth Holdings's Upcoming Earnings

Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) will cut its spending by over 25% to meet the Q4 break-even target as the company gears up to expand into Europe.
What Happened: "We have majorly merged the R&amp;D resources of the NIO brand, Amo brand, and the Fly brand to further improve the overall efficiency of our R&amp;D activities," company CEO William Li said at Nio's earnings call with Investors on Tuesday.
He then went on to say that the company's efforts to improve efficiency by consolidating teams, as well as roles, will result in "much tighter control over spending."
"In Q4, as we also have the breakeven target, we aim to control our R&amp;D expenses to be within 2 to 2.5 billion Yuan (about $278 &#8211; $347 million) per quarter. That represents a 20 to 25% year-over-year decrease from last year." Li said.
The CEO also touched upon Nio's global plans. "In international expansion, NIO has partnered with more than 10 local partners in over 15 core markets worldwide," before adding that the company will introduce the Firefly EV by Q3 in "various markets" throughout the globe.
Why It Matters: Nio reported a 40.1% YoY increase in deliveries at <a href="https://www.benzinga.com/markets/large-cap/25/06/45745834/nio-stock-drops-after-q1-results-and-outlook-disappoints-the-street-margins-shrink">the earnings call</a>, delivering 23,900 vehicles in April 2025 and 23,231 vehicles in May 2025. However, the automaker reported a 38.9% decline in revenue.
The company also reported a 13.1% increase in <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45717955/chinas-nio-clocks-13-deliveries-growth-in-may-tesla-lags">monthly deliveries for May</a>, including 13,270 vehicles from Nio as well as deliveries from subsidiaries Onvo and Firefly.
The Firefly EV, which was supposed to launch earlier, has been delayed by the company and Nio is also said to be developing <a href="https://www.benzinga.com/25/04/44915240/tesla-rival-nio-delays-the-european-launch-of-firefly-ev-report">right-hand drive variants</a> of the car for the UK and SEA.
Price Action: NIO gained 2.27% in Pre-market and is currently trading on the NYSE at $3.61, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45763345/amid-us-china-trade-war-global-automakers-warn-beijings-curbs-on-rare-earth-metals-could-significantly-impact-production">Amid US-China Trade War, Global Automakers Warn Beijing&#8217;s Curbs On Rare Earth Metals Could Significantly Impact Production</a></li>
</ul>
Photo courtesy: Robert Way / Shutterstock.com

Tesla Rival Nio Says It Will Cut R&D Spending By Around 25% To Meet 'Breakeven Target' Amid Europe Expansion Plans

Financial giants have made a conspicuous bearish move on Dollar General. Our analysis of options history for Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) revealed 9 unusual trades.
Delving into the details, we found 11% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $285,060, and 7 were calls, valued at $762,698.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $165.0 for Dollar General during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Dollar General's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Dollar General's whale trades within a strike price range from $55.0 to $165.0 in the last 30 days. 
<h3>Dollar General Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749052862_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$60.8</td>
<td>$56.55</td>
<td>$58.6</td>
<td>$55.00</td>
<td>$293.0K</td>
<td>120</td>
<td align="right">50</td>
</tr>
<tr>
<td>DG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.35</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$110.00</td>
<td>$256.0K</td>
<td>3.3K</td>
<td align="right">886</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$54.45</td>
<td>$54.45</td>
<td>$54.45</td>
<td>$165.00</td>
<td>$217.8K</td>
<td>0</td>
<td align="right">0</td>
</tr>
<tr>
<td>DG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$13.15</td>
<td>$12.2</td>
<td>$13.15</td>
<td>$99.00</td>
<td>$68.3K</td>
<td>1.1K</td>
<td align="right">52</td>
</tr>
<tr>
<td>DG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.85</td>
<td>$7.4</td>
<td>$8.85</td>
<td>$115.00</td>
<td>$67.2K</td>
<td>187</td>
<td align="right">76</td>
</tr>
</tbody>
</table>

<h3>About Dollar General</h3>
With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged food, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.
Having examined the options trading patterns of Dollar General, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Dollar General Standing Right Now?</h3>
<ul>
<li>With a volume of 2,552,178, the price of DG is down -1.76% at $110.59. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 85 days.</li>
</ul>
<h3>Expert Opinions on Dollar General</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $107.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Market Perform rating on Dollar General with a target price of $100. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Dollar General with a target price of $85. 
&#x2A; An analyst from JP Morgan persists with their Neutral rating on Dollar General, maintaining a target price of $95. 
&#x2A; Showing optimism, an analyst from Oppenheimer upgrades its rating to Outperform with a revised price target of $130. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Dollar General, which currently sits at a price target of $128. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Dollar General with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Check Out What Whales Are Doing With Dollar General

High-rolling investors have positioned themselves bullish on Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in COF often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Capital One Finl. This is not a typical pattern.
The sentiment among these major traders is split, with 54% bullish and 27% bearish. Among all the options we identified, there was one put, amounting to $39,480, and 10 calls, totaling $578,154.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $125.0 and $230.0 for Capital One Finl, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Capital One Finl's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Capital One Finl's whale activity within a strike price range from $125.0 to $230.0 in the last 30 days. 
<h3>Capital One Finl 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749052857_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.4</td>
<td>$3.1</td>
<td>$3.4</td>
<td>$200.00</td>
<td>$170.0K</td>
<td>5.3K</td>
<td align="right">500</td>
</tr>
<tr>
<td>COF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$76.5</td>
<td>$74.3</td>
<td>$75.97</td>
<td>$125.00</td>
<td>$75.9K</td>
<td>40</td>
<td align="right">0</td>
</tr>
<tr>
<td>COF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$29.6</td>
<td>$29.0</td>
<td>$29.18</td>
<td>$185.00</td>
<td>$55.4K</td>
<td>250</td>
<td align="right">19</td>
</tr>
<tr>
<td>COF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$1.45</td>
<td>$1.45</td>
<td>$1.45</td>
<td>$202.50</td>
<td>$46.1K</td>
<td>1.4K</td>
<td align="right">323</td>
</tr>
<tr>
<td>COF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$0.75</td>
<td>$0.6</td>
<td>$0.6</td>
<td>$212.50</td>
<td>$45.0K</td>
<td>188</td>
<td align="right">750</td>
</tr>
</tbody>
</table>

<h3>About Capital One Finl</h3>
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Having examined the options trading patterns of Capital One Finl, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Capital One Finl</h3>
<ul>
<li>With a trading volume of 911,054, the price of COF is down by -0.81%, reaching $194.05.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 48 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Capital One Finl</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $233.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Capital One Finl, which currently sits at a price target of $233. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Capital One Finl, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

A Closer Look at Capital One Finl's Options Market Dynamics

Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-06-05. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Ciena will report an earnings per share (EPS) of $0.52.
Ciena bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.23, leading to a 3.83% increase in the share price on the subsequent day.
Here's a look at Ciena's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.41</td>
<td>0.65</td>
<td>0.26</td>
<td>0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.64</td>
<td>0.54</td>
<td>0.35</td>
<td>0.27</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>6.0%</td>
<td>-5.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1749052857_0_0.png" alt="eps graph" />
<h3>Performance of Ciena Shares</h3>
Shares of Ciena were trading at $83.26 as of June 03. Over the last 52-week period, shares are up 74.96%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Opinions on Ciena</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Ciena.
Analysts have given Ciena a total of 14 ratings, with the consensus rating being Neutral. The average one-year price target is $79.93, indicating a potential 4.0% downside.
<h3>Understanding Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Juniper Networks, F5 and Lumentum Holdings, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Juniper Networks, with an average 1-year price target of $40.0, suggesting a potential 51.96% downside.</li>
<li>Analysts currently favor an Neutral trajectory for F5, with an average 1-year price target of $281.12, suggesting a potential 237.64% upside.</li>
<li>Analysts currently favor an Buy trajectory for Lumentum Holdings, with an average 1-year price target of $84.3, suggesting a potential 1.25% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Juniper Networks, F5 and Lumentum Holdings, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciena</td>
<td>Neutral</td>
<td>3.33%</td>
<td>$471.82M</td>
<td>1.59%</td>
</tr>
<tr>
<td>Juniper Networks</td>
<td>Neutral</td>
<td>11.43%</td>
<td>$754.70M</td>
<td>1.33%</td>
</tr>
<tr>
<td>F5</td>
<td>Neutral</td>
<td>7.30%</td>
<td>$590.16M</td>
<td>4.44%</td>
</tr>
<tr>
<td>Lumentum Holdings</td>
<td>Buy</td>
<td>16.02%</td>
<td>$122.50M</td>
<td>-5.03%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Ciena ranks in the middle among its peers for revenue growth, with a growth rate of 3.33%. It is at the bottom for gross profit at $471.82M. Ciena is also at the bottom for return on equity at 1.59%.
<h3>All You Need to Know About Ciena</h3>
Ciena Corp is a network and technology company. It provides network hardware, software, and services that support the transport, switching, aggregation, service delivery, and management of video, data, and voice traffic on communications networks. It serves various industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises world-wide. The business activities function through Networking Platforms which generates maximum revenue; Platform Software and Services; Blue Planet Automation Software, and Global Services segments. Geographically, the company derives a majority of its revenue from the Americas, and the rest from the Asia-Pacific (APAC), and Europe, Middle East, and Africa (EMEA) region.
<h3>Key Indicators: Ciena's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Ciena's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.33% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.16%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ciena's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.59%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Ciena's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.79%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Ciena's debt-to-equity ratio is below the industry average at 0.57, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/CIEN/earnings">To track all earnings releases for Ciena visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CIEN

Insights Ahead: Ciena's Quarterly Earnings

Elon Musk's brain-computer interface company Neuralink has raised $600 million in new funding at a $9 billion valuation, according to <a href="https://www.semafor.com/article/05/27/2025/elon-musks-neuralink-raises-fresh-cash-at-9b-valuation">Semafor</a>. The fundraising round follows the company's first human implant earlier this year and expands its efforts to develop medical applications for its brain chip technology.
Musk has previously stated that humans may be able to surf the web with their thoughts by the end of 2030, Reuters reported. The claim has drawn renewed attention amid the funding news. In January, <a href="https://www.technologyreview.com/2025/01/16/1110017/what-to-expect-from-neuralink-in-2025/">MIT Technology Review</a> noted that neuroscience experts have questioned the feasibility of this timeline.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
<h2 class="wp-block-heading">Clinical Trials Underway</h2>
<a href="https://www.benzinga.com/news/24/05/39053422/elon-musks-neuralink-initiates-brain-implant-study-aims-to-enroll-3-patients-for-revolutionary-digit">Neuralink began human trials</a> in 2024 after receiving U.S. Food and Drug Administration approval to implant its brain-computer interface, or BCI, in paralysis patients. The first participant, Noland Arbaugh, underwent surgery in January 2024 and was later shown controlling a computer cursor and playing online chess using only his thoughts, according to Reuters.
In May 2024, Neuralink registered a clinical study in the U.S. government trials database, aiming to enroll three participants. The company is also expanding its trial footprint internationally, having received <a href="https://www.benzinga.com/24/11/42103314/elon-musks-neuralink-gets-green-light-to-launch-brain-chip-trial-in-canada-recruitment-is-now-open">approval from Health Canada</a> in November 2024 to recruit six patients for a study testing the device's safety and efficacy in enabling cursor movement through brain activity.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;&nbsp;
While early demonstrations suggest meaningful progress, the technology remains highly experimental. Neuralink is currently conducting an <a href="https://www.themiamiproject.org/neuralink/">early feasibility study</a> called the Precise Robotically Implanted Brain-Computer Interface, with three participants implanted. The company has not yet registered a pivotal trial — the FDA-required phase for commercial approval — and continues to modify its device design, including electrode and surgical robot upgrades, according to MIT Technology Review.
<h2 class="wp-block-heading">Valuation Surges Amid Musk's AI Risk Narrative</h2>
Neuralink's valuation has risen sharply to $9 billion, up from an estimated $5 billion in mid-2023, according to Semafor. The publication reported that the recent funding round drew support from existing investors aligned with Elon Musk's other companies, including Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and SpaceX.
Musk has repeatedly positioned Neuralink as a safeguard against artificial intelligence threats. In a May 2 <a href="https://x.com/elonmusk/status/1918188145549468135">post on X</a>, he stated that Neuralink's brain chips must become widely available to ensure humans remain competitive as AI advances. He previously told <a href="https://edition.cnn.com/2023/04/17/tech/elon-musk-ai-warning-tucker-carlson">CNN</a> in 2023 that brain-computer interfaces could help reduce civilizational risk posed by artificial general intelligence.
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
<h2 class="wp-block-heading">Industry Context And Competitors</h2>
The global BCI market is projected to reach $6.52 billion by 2030, growing at a compound annual growth rate of 18.15% from 2025 to 2030, according to <a href="https://www.grandviewresearch.com/industry-analysis/brain-computer-interfaces-market">Grand View Research</a>.&nbsp;
Competitors are also gaining traction. <a href="https://www.reuters.com/technology/musks-neuralink-faces-federal-probe-employee-backlash-over-animal-tests-2022-12-05/">Synchron</a> was the first to receive FDA approval to implant a BCI in U.S. patients, and Precision Neuroscience recently <a href="https://www.globenewswire.com/news-release/2025/04/17/3063418/0/en/Precision-Neuroscience-Receives-FDA-Clearance-for-High-Resolution-Cortical-Electrode-Array.html">announced</a> regulatory clearance for its minimally invasive device.&nbsp;
As Neuralink expands its human trials, it faces pressure to keep pace with rivals and regulatory scrutiny. According to Reuters, FDA found quality control issues in the company's animal research lab, and U.S. Department of Agriculture's Inspector General have raised concerns over the pace and integrity of its experiments.
<h2 class="wp-block-heading">Looking Ahead</h2>
With significant competition, regulatory hurdles, and ethical concerns in play, Neuralink's ability to deliver on Musk's ambitious timeline will remain under close watch by investors, scientists, and the public alike.
Read Next: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
Image: Shutterstock

'Web-Surfing With Your Brain' by 2030? Neuralink's $9B Valuation Sparks Debate Over Musk's Telepathy Timeline

Investors with a lot of money to spend have taken a bearish stance on Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with U, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 16 options trades for Unity Software.
This isn't normal.
The overall sentiment of these big-money traders is split between 43% bullish and 56%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $174,636, and 15, calls, for a total amount of $558,876.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $42.0 for Unity Software during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Unity Software options trades today is 5883.5 with a total volume of 16,746.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Unity Software's big money trades within a strike price range of $20.0 to $42.0 over the last 30 days.
<h3>Unity Software 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749052852_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$5.9</td>
<td>$4.9</td>
<td>$5.67</td>
<td>$25.00</td>
<td>$174.6K</td>
<td>30</td>
<td>308</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.33</td>
<td>$1.2</td>
<td>$1.29</td>
<td>$42.00</td>
<td>$51.6K</td>
<td>1.4K</td>
<td>400</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.03</td>
<td>$1.01</td>
<td>$1.03</td>
<td>$30.00</td>
<td>$51.1K</td>
<td>38.6K</td>
<td>2.9K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$0.6</td>
<td>$0.52</td>
<td>$0.58</td>
<td>$28.00</td>
<td>$46.8K</td>
<td>1.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1.53</td>
<td>$1.52</td>
<td>$1.52</td>
<td>$36.00</td>
<td>$45.9K</td>
<td>606</td>
<td>359</td>
</tr>
</tbody>
</table>

<h3>About Unity Software</h3>
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
Following our analysis of the options activities associated with Unity Software, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Unity Software</h3>
<ul>
<li>Currently trading with a volume of 6,277,297, the U's price is up by 5.71%, now at $27.7. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 64 days.</li>
</ul>
<h3>What Analysts Are Saying About Unity Software</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $28.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Unity Software with a target price of $30. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Unity Software with a target price of $28. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Unity Software, maintaining a target price of $25. 
&#x2A; In a positive move, an analyst from Jefferies has upgraded their rating to Buy and adjusted the price target to $29. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Unity Software, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on Unity Software Options

In the current session, the stock is trading at $136.76, after a 0.09% spike. Over the past month, Live Nation Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) stock increased by 4.23%, and in the past year, by 51.54%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1749052838_0.png" alt="Past Year Chart" />

<h3>Evaluating Live Nation Entertainment P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 365.98 in the Entertainment industry, Live Nation Entertainment Inc. has a lower P/E ratio of 46.32. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749052838_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Live Nation Entertainment

ADMA Biologics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NYSE">ADMA</a>) short percent of float has risen 8.03% since its last report. The company recently reported that it has 13.33 million shares sold short, which is 6.86% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>ADMA Biologics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749052834_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ADMA Biologics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ADMA Biologics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, ADMA Biologics's peer group average for short interest as a percentage of float is 12.93%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ADMA

How Is The Market Feeling About ADMA Biologics?

Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) shares traded under pressure on Wednesday morning, despite reporting on Tuesday that it had achieved <a href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs">healthy same-store sales growth</a>.
The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<h1 class="wp-block-heading">BofA Securities On Dollar General</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad8d48b85e930001f97170/robert-ohmes">Analyst Robert Ohmes</a> maintained a Buy rating, while raising the price target from $115 to $135.
Dollar General reported fiscal first-quarter earnings of $1.78 per share, significantly beating Street expectations of $1.47 per share, Ohmes said in a note. Same-store sales grew 2.4%, much higher than the consensus of 1.1%, driven by 2.7% ticket growth, while traffic declined by 0.3%, he added.
Management raised the low end of their full-year earnings guidance by 10 cents per share to $5.20-$5.80 per share, "reflecting 1Q upside as well as tariff impact uncertainty," the analyst stated. Dollar General's Back to Basics initiatives seem to be working, "which should continue driving efficiencies over time," he further wrote.
<h1 class="wp-block-heading">Truist Securities On Dollar General</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59493ca670ed7a0001097213/scot-ciccarelli">Analyst Scot Ciccarelli</a> reiterated a Hold rating, while lifting the price target from $93 to $112.
Dollar General's quarterly results were better than was initially expected, Ciccarelli said. The company delivered positive comps in all three months of the quarter and across all four of its merchandise categories, he added.
"While we think it's fair to question the sustainability of these trends (tariffs, consumer trends, product mix, etc.), the year is off to a solid start," the analyst wrote. The company raised its full-year comps guidance by 30 basis points (bps) to 1.5%-2.5% and its earnings outlook to $5.20-$5.80 per share, from $5.10-$5.80 per share, the analyst stated.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">JPMorgan On Dollar General</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586bcbd9351b9b0001ab738c/matthew-boss">Analyst Matthew Boss</a> reaffirmed a Neutral rating, while raising the price target from $88 to $95.
Dollar General reported its earnings around 19% higher than Street expectations, with the outperformance being driven by same-store-sales growth of 2.4% versus a consensus of 1.3%, gross margin expanding by 78 bps to 31.0% and SG&amp;A deleverage of 77bps to 25.4%, Boss said.
Management has raised the low end of its 2025 revenue growth outlook to 3.7%-4.7%, up from its prior projection of 3.4%-4.4%, the analyst stated. The company indicated it could mitigate most of the potential tariff headwind by "negotiating cost concessions, shifting manufacturing to other countries where possible, re-engineering products, or finding substitute products," he further wrote.
<h1 class="wp-block-heading">Telsey Advisory Group On Dollar General</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e301e08430dee0001c88c8d/joseph-feldman">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e301e08430dee0001c88c8d/joseph-feldman">Joseph Feldman</a> maintained a Market Perform rating, while taking the price target higher from $100 to $120.
Dollar General posted operating margins of 5.5%, beating the consensus of 4.7%, Feldman said. Although the company's core lower-income consumers are facing spending constraints, the middle- and higher-income households are shopping more frequently and spending more, he added.
While traffic declined by 0.3%, "it was up 4% on a two-year stacked basis, and it has been positive in 2Q25-to-date," the analyst wrote. Dollar General's Back-to-Basics initiatives resulted in market share gains in both consumables and non-consumables, he further stated.
<h1 class="wp-block-heading">KeyBanc Capital Markets On Dollar General</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59009b5a0bd9910001e5f2aa/bradley-thomas">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59009b5a0bd9910001e5f2aa/bradley-thomas">Bradley Thomas</a> reiterated a Sector Weight rating on the stock.
Dollar General reported better-than-expected results, with its strategic initiatives taking hold, Thomas said. The company achieved positive comps in consumables, apparel, home and seasonal, with the latter two categories being up 3% in the quarter, he added.
"The gross margin outlook is favorable, supported by 60 bps lower shrink, which could continue this year and still leave 20 bps incremental improvement opportunity after 2025," he further wrote.
DG Price Action: Shares of Dollar General had declined by 1.76% to $110.61 at the time of publication on Wednesday.
Read More: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst"> </a> • <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst">Dollar General Boosts Annual Outlook Despite Ongoing Tariff Uncertainty</a>
Photo: Shutterstock

Analyst Color

Earnings Beats

Guidance

Dollar General Posts Convincing Q1 Earning Beat, 'The Year Is Off To A Solid Start,' Could Mitigate Most Potential Tariff Headwinds

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY

HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

Comments

Harmony Biosciences Hldgs

Vendite allo scoperto

Harmony Biosciences Hldgs (NASDAQ:HRMY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO